Arama Sonuçları - Cui, Chengxu

Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐cente... Yazar: Jiang, Zhichao, Sun, Yongkun, Zhang, Wen, Cui, Chengxu, Yang, Lin, Zhou, Aiping

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer Yazar: CUI, CHENGXU, SHU, CHANG, YANG, YI, LIU, JUNBAO, SHI, SHUPING, SHAO, ZHUJUN, WANG, NAN, YANG, TING, HU, SONGNIAN

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial Yazar: Zhang, Wen, Du, Chunxia, Sun, Yongkun, Yang, Lin, Cui, Chengxu, Jiang, Zhichao, Wang, Chengfeng, Wang, Jinwang, Zhou, Aiping

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer Yazar: Song, Yan, Qu, Tao, Zhang, Honggang, Sun, Yongkun, Cui, Chengxu, Chi, Yihebali, Zhang, Wen, Wang, Xingyuan, Yang, Lin

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens Yazar: Cui, Chengxu, Shu, Chang, Cao, Dandan, Yang, Yi, Liu, Junbao, Shi, Shuping, Shao, Zhujun, Wang, Nan, Yang, Ting, Liang, Hao, Zou, Shanshan, Hu, Songnian

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy Yazar: Shang, Bingqing, Cao, Chuanzhen, Jiang, Weixing, Shi, Hongzhe, Bi, Xingang, Cui, Chengxu, Shou, Jianzhong, Zheng, Shan, Zhang, Jin, Zhou, Aiping, Li, Changling, Ma, Jianhui

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial Yazar: Qin, Shukui, Bi, Feng, Gu, Shanzhi, Bai, Yuxian, Chen, Zhendong, Wang, Zishu, Ying, Jieer, Lu, Yinying, Meng, Zhiqiang, Pan, Hongming, Yang, Ping, Zhang, Helong, Chen, Xi, Xu, Aibing, Cui, Chengxu, Zhu, Bo, Wu, Jian, Xin, Xiaoli, Wang, Jufeng, Shan, Jinlu, Chen, Junhui, Zheng, Zhendong, Xu, Li, Wen, Xiaoyu, You, Zhenyu, Ren, Zhenggang, Liu, Xiufeng, Qiu, Meng, Wu, Liqing, Chen, Feng

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label pha... Yazar: Xu, Jianming, Li, Yi, Fan, Qingxia, Shu, Yongqian, Yang, Lei, Cui, Tongjian, Gu, Kangsheng, Tao, Min, Wang, Xiuwen, Cui, Chengxu, Xu, Nong, Xiao, Juxiang, Gao, Quanli, Liu, Yunpeng, Zhang, Tao, Bai, Yuxian, Li, Wei, Zhang, Yiping, Dai, Guanghai, Ma, Dong, Zhang, Jingdong, Bai, Chunmei, Huang, Yunchao, Liao, Wangjun, Wu, Lin, Chen, Xi, Yang, Yan, Wang, Junye, Ji, Shoujian, Zhou, Hui, Wang, Yan, Ma, Zhuo, Wang, Yanqi, Peng, Bo, Sun, Jiya, Mancao, Christoph

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim